It is recommended to perform serial measure­ments of natriuretic peptides in dialysis patients (preferably NT proBNP), if available, as they may help in the assessment of volume overload, identification and control of HF associated with dialysis CKD, and especially in predicting the risk of CV outcomes and death (Class I/Level B). Here, NPPB is linked to chronic kidney disease.